There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Augmedix (AUGX – Research Report) and ReShape Lifesciences (RSLS – Research Report) with bullish sentiments.
Augmedix (AUGX)
In a report released yesterday, Allen Klee from Maxim Group reiterated a Buy rating on Augmedix, with a price target of $8.00. The company’s shares closed last Tuesday at $4.87, close to its 52-week high of $5.36.
According to TipRanks.com, Klee is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Augmedix with a $6.83 average price target, a 61.1% upside from current levels. In a report released yesterday, B.Riley Financial also reiterated a Buy rating on the stock with a $6.50 price target.
See the top stocks recommended by analysts >>
ReShape Lifesciences (RSLS)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on ReShape Lifesciences. The company’s shares closed last Tuesday at $1.28, close to its 52-week low of $1.17.
According to TipRanks.com, Vendetti is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The the analyst consensus on ReShape Lifesciences is currently a Moderate Buy rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AUGX:
- Augmedix Delivers 47% Revenue Growth and Expanded Gross Margins for Second Quarter of 2023
- AUGX Earnings this Week: How Will it Perform?
- Augmedix to Announce Second Quarter 2023 Financial Results and Host Investor Conference Call on August 7, 2023
- Augmedix extends term loan facility, finalizes terms for line of credit
- Augmedix Extends Term Loan Facility and Finalizes Terms for Equity Line of Credit
